Received: 15 May 2019
Accepted: 25 September 2019
First Online: 11 October 2019
Ethics approval and consent to participate
: This study was approved by the Institutional Review Board of Keio University School of Medicine (2014336). In addition, each university that participated in this study obtained permission from its Institutional Review Board or equivalent committee. This study was conducted according to the principles of the Declaration of Helsinki. Informed consent was obtained from all individual participants included in the study.
: Not applicable.
: The authors have no conflict of interest related to the contents of the work. However, outside the submitted work, Taishiro Kishimoto has received consultant fees from Dainippon Sumitomo, Novartis and Otsuka, speaker’s honoraria from Banyu, Eli Lilly, Dainippon Sumitomo, Janssen, Novartis, Otsuka and Pfizer, and grant support from the Pfizer Health Research, Takeda, Tanabe-Mitsubishi, Dainippon-Sumitomo, Otsuka and Mochida; Masaru Mimura has received grants and/or speaker’s honoraria from Abbvie, Asahi Kasei, Astellas, Chugai, Cracie, Daiichi Sankyo, Dainippon-Sumitomo, Eisai, Eli Lilly, Fuji Film, Janssen, Meiji Pharma, Mochida, MSD, Novartis, Ono, Otsuka, Pfizer, Shionogi, Takeda, and Yoshitomi Pharmaceutical within the past 3 years; Kazuo Tsubota is a consultant for Santen Pharmaceutical Co., Ltd., Otsuka Pharmaceutical Co., Ltd., AMO Japan KK, Novaliq GmnH, MediProduct Inc., NIDEK Co, Ltd. and holds patents or patents pending with Jins Co., Ltd., Kowa Comp, Tsubota Laboratory, Inc., and Echo Denki. Momoko Kitazawa, Michitaka Yoshimura, Hidefumi Hitokoto, Mayu Murata, Yuka Sato-Fujimoto and Kazuno Negishi have nothing to disclose.